Amivantamab plus chemotherapy vs. chemotherapy as first-line treatment in Chinese mainland patients with EGFR exon 20 insertion non-small cell lung cancer: Subgroup analysis of the randomized PAPILLON trial
A new antibody drug combined with chemotherapy doubled progression-free survival for a specific lung cancer mutation in Chinese patients, validating global trial results locally.
A prespecified subgroup analysis of the phase 3 PAPILLON trial in 87 Chinese patients with EGFR exon 20 insertion-mutant NSCLC showed that first-line amivantamab plus carboplatin-pemetrexed nearly doubled progression-free survival (12.3 vs 6.7 months, HR 0.47) and significantly improved ORR (71.8% vs 48.9%) versus chemotherapy alone. Results were fully consistent with the global PAPILLON population, supporting amivantamab-based first-line therapy for EGFR exon 20 insertion NSCLC in Chinese patients — an important population-specific validation.
What the study was
- Study design
- Phase 3 RCT prespecified subgroup analysis
- Population
- Chinese mainland patients with treatment-naïve advanced/metastatic NSCLC harboring EGFR exon 20 insertion mutations
- Sample size
- 87
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Chinese Medical Journal (English)
Why it surfaced
Phase 3 data confirming amivantamab + chemo superiority in EGFR exon 20 insertion NSCLC (high unmet need; ~2-3% of NSCLC with limited options) in Chinese patients; population-specific confirmation of regulatory importance; CC-BY-NC-ND open access
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.